NVO executive sells 12,000 B-shares for DKK 3.912M; Form 6-K notice
Rhea-AI Filing Summary
Novo Nordisk disclosed that Ludovic Helfgott, Executive Vice President, sold 12,000 Novo Nordisk B shares at DKK 326 per share on Nasdaq Copenhagen on 2025-08-08, for an aggregate amount of DKK 3,912,000. The company reported the transaction under Article 19 of Regulation No. 596/2014, with the sale recorded as an initial notification by the named executive.
The announcement also reiterates basic company information: Novo Nordisk markets its B shares on Nasdaq Copenhagen and ADRs on the New York Stock Exchange under the ticker NVO, employs about 78,400 people, and sells products in roughly 170 countries.
Positive
- Timely regulatory disclosure of an insider transaction under Article 19, including name, role, ISIN, price, volume, and trading venue
Negative
- None.
Insights
TL;DR: Executive sale of 12,000 B-shares for DKK 3.912M reported; routine disclosure, likely neutral for near-term fundamentals.
The filing records a single-purpose sale: 12,000 Novo Nordisk B shares at DKK 326 each, executed on Nasdaq Copenhagen on 2025-08-08, aggregating DKK 3,912,000. This is presented as an initial notification by Ludovic Helfgott, Executive Vice President. From a market-impact perspective, the disclosed size appears modest relative to a global pharmaceutical issuer, and the document is a compliance disclosure under Article 19 rather than an operational or financial update. There are no accompanying changes to company guidance, capital structure, or operational metrics in this filing.
TL;DR: Timely insider disclosure demonstrates regulatory compliance and governance transparency; the sale itself is not presented as material to company operations.
The report fulfils statutory reporting obligations by naming the person involved, the role (Executive Vice President), the instrument (Novo Nordisk B shares, ISIN DK0062498333), the nature of the transaction (sale), price and volume, the aggregate value, and the trading venue. Such granularity supports transparency for stakeholders monitoring insider activity. The filing contains no indication of policy changes, related-party transfers, or other governance events beyond the single sale.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 12, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 326.00 | 12,000 | ||||
| d) |
Aggregated information
|
12,000 shares DKK 3,912,000.00 |
|||
| e) | Date of the transaction | 2025-08-08 | |||
| f) | Place of the transaction | Nasdaq Copenhagen |
|||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 3 of 3
Contacts for further information
| Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 23/ 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 12, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
What insider transaction did Novo Nordisk (NVO) report?
What was the aggregated value of the reported sale in the 6-K?
When and where was the transaction executed for NVO?
Who submitted the notification and what was their role?
Where are Novo Nordisk B shares and ADRs listed?
